Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avant Brands's Enterprise Value for the quarter that ended in May. 2026 was C$19.18 Mil.
Avant Brands's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-9.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avant Brands EV-to-EBIT Related Terms
Avant Brands EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Avant Brands's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avant Brands's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avant Brands EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avant Brands's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avant Brands's EV-to-EBIT falls into.
Avant Brands's current Enterprise Value is C$18.13 Mil.
Avant Brands's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-9.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avant Brands (TSX:AVNT) has a EV-to-EBIT of -1.88 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avant Brands and its competitors. According to the industry distribution chart, Avant Brands ranks #999999 out of 686 companies in the Drug Manufacturers industry.
Is Avant Brands' EV-to-EBIT too high?
Avant Brands' current EV-to-EBIT is -1.88. Based on the distribution chart, Avant Brands ranks #999999 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Avant Brands has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avant Brands' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avant Brands ranks #999999 out of 686 companies for EV-to-EBIT. This places Avant Brands in the lower half of its industry. The industry median EV-to-EBIT is 15.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avant Brands and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avant Brands's current EV-to-EBIT is -1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avant Brands stock overvalued right now?
Based on GuruFocus' analysis, Avant Brands (TSX:AVNT) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.95, compared to a current price of C$0.58 — trading 38.9% below its estimated fair value. The current EV-to-EBIT is -1.88. Avant Brands' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Avant Brands (TSX:AVNT), the current EV-to-EBIT is -1.88 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avant Brands (TSX:AVNT) Overvalued in 2026?
Based on GuruFocus' analysis, Avant Brands stock appears to be undervalued.
The current stock price of C$0.58 is trading 38.9% below its estimated GF Value™ of C$0.95.
GuruFocus considers Avant Brands to be Possible Value Trap.
Key valuation signals for TSX:AVNT:
EV-to-EBIT: -1.88
GF Value™: C$0.95 vs. price of C$0.58 (38.9% below fair value)
No single metric tells the full story. See the TSX:AVNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avant Brands Inc operating in the cannabis industry, engages in the cultivation, production, marketing, and sale of cannabis products. Its product portfolio mainly consists of dried cannabis flower and related cannabis products, with the company managing the entire value chain from cultivation and harvesting to processing, packaging, and distribution, generating revenue upon delivery of products to customers. It operates in Canada.
31GF Score
Get the complete analysis for TSX:AVNT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:AVNT has been successfully added to your 
